Dr Reddy's Labs (DRREDDY) Share News & Alerts

Buy, Sell Or Hold: IRCTC, SBI, Hindustan Copper, M&M, Paras Defence, Dr Reddy's Laboratories — Ask Profit

▲ Bullish +1.48%

The analysis offers technical consensus and defensive positioning advice for this pharma major, guiding positional traders on key accumulation zones without changing long-term fundamentals.

These 7 stocks reported declining EPS for 4 straight quarters

▼ Bearish +3.21%

Four consecutive quarters of declining EPS indicate persistent operational headwinds and margin pressure for Dr. Reddy's. Swing traders are likely to view this sustained earnings deterioration bearishly, leading to short-to-medium term institutional distribution and price weakness.

CDSCO Issues Revised Regulatory Guidelines For Drug, Cosmetics And Medical Devices Sampling

▼ Bearish +4.77%

Dr. Reddy's Laboratories is likely to see minor near-term consolidation as inspectors target high-risk products and wide jurisdiction sampling. The pressure of rapid laboratory timelines and stricter retail channel checks could dampen domestic formulation margins over a 1-2 week trading horizon.

Stocks to watch: LIC, ITC, RVNL, Dr Reddy's among 10 shares in focus today; check list here

▲ Bullish +1.84%

Dr. Reddy's Laboratories is in the spotlight following the strategic domestic launch of its oral semaglutide biosimilar under the brand name 'Obeda' for type 2 diabetes. This high-margin product introduction opens a substantial new market segment, creating a multi-week structural upside narrative.

Stocks in news: ITC, Nykaa, Lenskart, Ola Electric, IndusInd Bank

▲ Bullish +1.84%

The launch of the oral semaglutide biosimilar 'Obeda' introduces a major high-margin product into India's massive diabetes market. This value-accretive product launch acts as a clear multi-day bullish driver for the stock.

Dr. Reddy’s launches Semaglutide tablets in India

▲ Bullish +1.84%

The launch of a heavily undercut oral semaglutide biosimilar targeting the massive $1 billion Indian GLP-1 market represents a significant new revenue catalyst for Dr. Reddy's. By offering tablets starting at just Rs 99 per pill, the company successfully undercuts global innovator Novo Nordisk and primary generic peer Torrent Pharma, priming it for rapid market share capture. This high-margin, in-house formulation provides strong visibility for structural earnings upgrades, making it an ideal long candidate for swing and positional traders looking for multi-week upside momentum.

Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda In India

▲ Bullish +1.84%

Dr. Reddy's Laboratories is directly impacted by the commercial rollout of its oral semaglutide biosimilar (Obeda) in India, capturing a major chunk of the highly lucrative diabetes and obesity market. Developed completely in-house, this high-margin drug launch acts as a significant multi-quarter revenue catalyst. For swing and positional traders, this creates a clear bullish sentiment capable of triggering a multi-day momentum rally or a structural breakout.

Five Stocks To Buy: BHEL, Dr Reddy's, KPIT Tech And More | May 20, 2026

▲ Bullish +0.39%

Inclusion in a major financial news brokerage recommendation list boosts retail and positional trader confidence. It is expected to see a minor positive price reaction over a short-term swing timeframe.

Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27

▲ Bullish +6.28%

The stock is currently digestng a severe 86% profit drop due to one-off inventory adjustments and US pricing pressure. However, the definitive FY27 roadmap featuring the Semaglutide (GLP-1) launch—a massive global growth category—provides a clear fundamental floor for positional traders. Expect a multi-day stabilization followed by a gradual upward re-rating as the market shifts focus from past earnings misses to future high-margin (>50% gross margin) potential.

Dr. Reddy’s Q4 dips 86% on lower sales, multiple one offs to ₹221 crore

▼ Bearish +0.77%

The massive 86% profit slump was driven by a combination of structural headwinds in the US market and over ₹800 crore in one-off charges, including a significant shelf stock adjustment for its key cancer drug, Lenalidomide. This has caused a catastrophic margin contraction from ~23% to 5%, which severely damages the company's near-term earnings visibility and historical premium valuation. Given the double-digit revenue decline and ongoing pricing pressure in generics, the stock is likely to face a multi-week de-rating as analysts slash forward estimates.

Dr Reddys Laboratories Ltd drops for fifth straight session

▼ Bearish +1.78%

The stock is under severe pressure following a massive earnings miss (86% PAT drop) driven by a ₹4,530 crore inventory adjustment and impairment of cancer therapy assets. Combined with a 12% revenue decline and weakening US generic margins, the stock has broken short-term moving averages, likely leading to a bearish consolidation phase or further downward re-rating over the next few weeks as analysts slash price targets.

Dr Reddy's Laboratories shares volatile after a 86% YoY decline in Q4 profit. Should you buy?

▼ Bearish +0.64%

The stock is reacting to a significant bottom-line miss with an 86% profit slump, which typically triggers institutional selling. While the initial price action is volatile, such a sharp decline in earnings often leads to a multi-day downward adjustment as analysts revise their price targets. For a positional trader, this represents a breakdown of fundamental support levels.

Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in

▼ Bearish +1.64%

The massive 86% drop in net profit combined with delays in key product launches like Semaglutide creates a fundamental breakdown in the growth story. Multiple top-tier brokerages cutting price targets simultaneously acts as a bearish catalyst for positional traders, likely leading to a multi-day correction as institutional investors rebalance their holdings.

Stock Picks Today: Grasim, Dr Reddy's, Dixon Tech, Berger Paints, And More On Brokerages' Radar

▼ Bearish +3.87%

Dr. Reddy's is expected to face bearish pressure in the short term following a 'weak Q4' which prompted target price cuts from firms like Motilal Oswal. For swing traders, the stock may remain sideways to negative as the market digests the earnings miss and reduced growth estimates.

Stocks to watch: Bharti Airtel, Tata Motors, Vodafone Idea among 10 shares in focus today

▼ Bearish +2.91%

Pfizer Declares Bumper Dividend Of Rs 75/Share Even As Q4 Profit Slides; Check Record Date

▼ Bearish +2.91%

An 86% crash in net profit due to impairment charges and lower North American sales is a major negative surprise. Expect significant selling pressure over a multi-day timeframe as analysts slash target prices.

Dr Reddy's Q4 results 2026: Profit plunges 86% YoY to ₹220 crore; board recommends a final dividend of ₹8

▼ Bearish +2.91%

The massive 86% drop in net profit is a significant negative surprise that typically leads to aggressive institutional selling. For a swing trader, this suggests a multi-day downward adjustment as the market revalues the company's immediate growth prospects and operational efficiency.

Q4 Results Live Updates: V-Guard Announces Dividend; All Eyes On Dixon Tech

▲ Bullish +5.88%

Dr. Reddy's is under the scanner for its US product concentration and biosimilar pipeline progress in Canada and the EU. As a defensive heavyweight, the result outcome will likely dictate the Nifty Pharma index's direction for the remainder of the week.

Stocks to buy: Sagar Doshi suggests Dr Reddys, Grasim, and HUL shares to buy

▼ Bearish +3.28%

Dr. Reddy's is expected to report a significant 34% YoY drop in net profit due to lower US sales, creating a bearish outlook for the pharmaceutical major ahead of its results. Swing traders should watch the 1,035 crore profit mark as a key benchmark for potential reversal or further decline.

Q4 results 2026: Tata Power to Dr Reddy's among companies to declare Q4 results today; full list here

▼ Bearish +3.66%

As a major Nifty 50 component reporting results, any deviation from estimates will likely cause a multi-day trend shift in the pharma sector.